IPP Bureau
Novartis to acquire Gyroscope Therapeutics for up to US $ 1.5 bn
By IPP Bureau - December 22, 2021
Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with Geographic atrophy
Thermo Fisher Scientific updates its Covid-19 panel to detect Omicron
By IPP Bureau - December 22, 2021
The TaqMan SARS CoV-2 Mutation Panel is compatible with real-time PCR instruments already commonly used in laboratories around the world
Sputnik Light booster after Sputnik V effective against Omicron: Study
By IPP Bureau - December 22, 2021
Sputnik Light as a booster significantly increases virus neutralizing activity against Omicron based on sera 2-3 months after revaccination
AquaCentric Therapy opens up for treatment of autism care
By IPP Bureau - December 22, 2021
Autism spectrum disorder affects 78 million people and families worldwide
A 39-year-old patient with Covid-19 was saved with ECMO support
By IPP Bureau - December 22, 2021
Patient with acute Covid-19 infection treated at BGS Gleneagles Global Hospital
Stelis commissions vaccine facility in Bengaluru
By IPP Bureau - December 21, 2021
The company has started manufacturing the Sputnik Light vaccine
Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA
By IPP Bureau - December 21, 2021
Trastuzumab is monoclonal antibody used to treat human epidermal growth factor receptor 2 positive (HER2+) breast cancer and metastatic gastric cancers
CDSCO increases shelf life of Covaxin
By IPP Bureau - December 21, 2021
The approval of shelf life extension is based on the availability of additional stability data, which was submitted to the CDSCO
Novartis collaborates with BeiGene to strengthen immunotherapy pipeline
By IPP Bureau - December 21, 2021
Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
U.S. FDA approves first and only injectable option for HIV prevention
By IPP Bureau - December 21, 2021
Given as few as six times per year and demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV acquisition
Curran Biotech’s develops nano coating to combat Covid-19 variants
By IPP Bureau - December 21, 2021
The revolutionary new nano coating is easy to apply and rejects liquid-based contagions like COVID-19/SARS-CoV-2 and variants, influenzas, and rhinoviruses and is available via ready-to-use sprays or pre-treated air filters
NMPA approves CStone's NDA for Cejemly
By IPP Bureau - December 21, 2021
The NMPA approval is based on the positive data of GEMSTONE-302 study, a multi-center, randomized, double-blind, phase III study that evaluated the efficacy and safety of Cejemly or placebo in combination with chemotherapy in first-line stage IV NSCLC patients
Salesforce and Azim Premji Foundation launch VaxIT app to speed up Covid-19 vaccination
By IPP Bureau - December 21, 2021
The VaxIT app, developed on the Salesforce platform for Azim Premji Foundation and its partners, captures the status of vaccinations to help individuals plan and stay updated on their progress
Shilpa Medicare launch Prucalshil for treatment of constipation
By IPP Bureau - December 21, 2021
Prucalopride medicine in the form of Orally Disintegrating Strips are most convenient dosage form for geriatric patients
U.S. FDA approves ANI’s rifabutin capsules, launch soon
By IPP Bureau - December 21, 2021
The capsules are the generic version of the reference listed drug Mycobutin
